Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03846804
Other study ID # 1901296571
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 1, 2019
Est. completion date June 2, 2022

Study information

Verified date November 2023
Source Indiana University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the use of a blood test: Karius® plasma-based next-generation sequencing test (Karius Test), to see if we can detect and measure the infection causing agent in children with musculoskeletal infections (MSKI).


Description:

children admitted to Riley Hospital for Children (RHC) with musculoskeletal infections (osteomyelitis, septic arthritis, or pyomyositis) over a 12-month period will be prospectively enrolled. Eligible subjects will be identified by referral from the infectious diseases and orthopedic services at RHC. Blood samples will be obtained on the day of admission (within 48hrs), and 24 hours after the admission sample for real-time NGS (next-generation sequencing) testing at Karius Laboratory (Redwood City, CA). If a pathogen is identified by NGS, in either of the first two samples, subsequent samples will be sent every 48-72 hours while inpatient, and then collected every 1-2 weeks after hospital discharge, while being treated for MSKI (maximum 3 follow-up samples). If both of the initial inpatient NGS samples are negative, no further samples will be sent for NGS. Pathogen identification by NGS will be compared to standard cultures methods, and quantitative cfDNA (cell-free DNA) will be evaluated over time.


Recruitment information / eligibility

Status Completed
Enrollment 38
Est. completion date June 2, 2022
Est. primary completion date June 2, 2022
Accepts healthy volunteers No
Gender All
Age group 6 Months to 18 Years
Eligibility Inclusion Criteria: 1. 6 months (to ensure adequate blood volume drawn) to 18 years of age. 2. Strong clinical suspicion of MSKI as evidenced by fever, osteoarticular pain (e.g. tenderness to palpation of a joint, bone pain, or refusal to bear weight); and elevated ESR (erythrocyte sedimentation rate) or CRP (C-reactive protein). Exclusion Criteria: - Subjects will be excluded if they have clinical evidence suggesting an alternative diagnosis; inability or unwillingness to consent for the study

Study Design


Intervention

Diagnostic Test:
Karius Test
Next-generation sequencing of blood and synovial fluid samples for pathogen identification in children with musculoskeletal infections

Locations

Country Name City State
United States Riley Hospital for Children Indianapolis Indiana

Sponsors (2)

Lead Sponsor Collaborator
Indiana University Karius, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants With a Pathogen Identified by the Initial Karius Test (IP1) and Standard Culture Methods We evaluated the total number of participants that had a pathogen identified by the initial (IP1) Karius Test ("positive Karius Test").
We compared the results of the Karius Test to cultures (gold standard) for each participant. Karius Test results that matched cultures results (same genus and species) were considered "positive agreement".
We also evaluated at the number of participants who had negative cultures, but had a positive Karius Test.
Inpatient Sample 1 (IP1) - Within 48 hours of admission
Primary Number of Participants With a Pathogen Identified by the Karius Test (at Time Point IP2) and Standard Culture Methods We evaluated the total number of participants that had a pathogen identified by the Karius Test ("positive Karius Test") at time point IP2 (within 48 hours of the initial sample).
We compared the results of the Karius Test to those with a positive culture (gold standard) for each participant.
Karius Test results that matched cultures results (same genus and species) were considered "positive agreement".
Karius Test results that identified an organism different from the organism identified in culture were considered "discordant results" Karius Tests results that did not identify any organism were consider "negative"
Inpatient Sample 2 (IP2) - Within 48 hours of the initial sample
Secondary Microbial Cell Free DNA Level (cfDNA) in Molecules Per Microliter (MPM) We compared the microbial cfDNA level (on initial samples, IP1) between patients with non-severe MSKI to those with severe MSKI (defined as need for intensive care unit (ICU) care; infection in two or more non-contiguous anatomic sites (disseminated disease); need for more than 1 debridement procedure; deep vein thrombosis or thromboembolic disease; or pathologic fracture).
Only those with a positive agreement between initial Karius Test (IP1) and culture were analyzed (n=15).
Mann-Whitney U was used to compare median microbial cfDNA between those with non-severe vs. severe MSKI.
From hospital admission to hospital discharge, up to 3 months
Secondary Microbial Cell Free DNA (cfDNA) in Molecules Per Microliter (MPM) at Time Point IP1 We evaluated whether cfDNA level (in MPM) correlated with C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) and white blood cell count (WBC), common inflammatory markers followed in children with MSKI.
Spearman's correlation was used to compare the MPM value to the CRP, ESR and WBC
Inpatient Sample 1 (IP1) - Within 48 hours of admission
Secondary Microbial Cell Free DNA (cfDNA) in Molecules Per Microliter (MPM) at Time Point IP2 We evaluated whether cfDNA level (in MPM) correlated with C-reactive protein (a common inflammatory marker used to track inflammation in children with MSKI).
Spearman's correlation was used to compare the MPM value to the CRP
Inpatient Sample 2 (IP2) - Within 48 hours of the admission sample
Secondary Microbial Cell Free DNA (cfDNA) in Molecules Per Microliter (MPM) at Timepoint IP3 We evaluated whether cfDNA level (in MPM) correlated with C-reactive protein (a common inflammatory marker used to track inflammation in children with MSKI) at time point IP3 in participants with positive agreement between the Karius Test and culture.
Spearman's correlation was used to compare the MPM value to the CRP
Inpatient Sample 3 (IP3) - Within 48 hours of the second inpatient sample
Secondary Microbial Cell Free DNA (cfDNA) in Molecules Per Microliter (MPM) at Time Point IP4 We evaluated whether cfDNA level (in MPM) correlated with C-reactive protein (a common inflammatory marker used to track inflammation in children with MSKI). Inpatient Sample 4 (IP4) - Within 48 hours of the third inpatient sample
Secondary Microbial Cell Free DNA (cfDNA) in Molecules Per Microliter (MPM) at Time Point OP1 We evaluated whether cfDNA level (in MPM) correlated with C-reactive protein (a common inflammatory marker used to track inflammation in children with MSKI). Outpatient Sample 1 (OP1) - 1-2 weeks after hospital discharge
Secondary Microbial Cell Free DNA (cfDNA) in Molecules Per Microliter (MPM) at Time Point OP2 We evaluated whether cfDNA level (in MPM) correlated with C-reactive protein (a common inflammatory marker used to track inflammation in children with MSKI). Outpatient Sample 2 (OP2) - 3-6 weeks after hospital discharge
Secondary Microbial Cell Free DNA (cfDNA) in Molecules Per Microliter (MPM) at Time Point OP3 We evaluated whether cfDNA level (in MPM) correlated with C-reactive protein (a common inflammatory marker used to track inflammation in children with MSKI). Outpatient Sample 3 (OP3) - 6-8 weeks after hospital discharge
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04563325 - Oral-only Antibiotics for Bone and Joint Infections in Children Phase 4
Not yet recruiting NCT06402292 - Surgical Treatment of Osteoarticular Infections Using Bioactive Bone Substitute N/A
Active, not recruiting NCT04945434 - Clinical Effectiveness of S53P4 Bioactive Glass in Treatment of Long-bone Chronic Osteomyelitis N/A
Recruiting NCT06084754 - Effect of Pulsed Electromagnetic Field Stimulation on Localized Pediatric Osteomyelitis N/A
Recruiting NCT05177107 - Bacteriophage Therapy in Patients With Diabetic Foot Osteomyelitis Phase 2
Recruiting NCT04554108 - Acute Non-severe Osteomyelitis in Children - Outpatient Management Strategy With Oral Antibiotic Therapy Compared to a Standard Strategy With Conventional Hospitalization and Intravenous Antibiotic Therapy: a Randomized Open-label Non-inferiority Study With Bayesian and Medical-economic Analyses. N/A
Recruiting NCT02128256 - CERAMENTâ„¢|G - Bone Healing and Re-infection Prophylaxis Phase 4
Terminated NCT01612962 - Diagnostic Tests to Help Determine Osteomyelitis N/A
Terminated NCT03091439 - Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Patients With Osteomyelitis Phase 2
Recruiting NCT04936958 - RETR(Osteomyelitis)
Completed NCT03802552 - Cefadroxil and Cephalexin Drug Levels and Dosing in Pediatric Musculoskeletal Infections Phase 1
Completed NCT03559530 - Acinetobacter Baumannii-related Osteomyelitis: Clinical and Epidemiological Characterization
Completed NCT00324922 - Vancomycin Or Trimethoprim/Sulfamethoxazole for Methicillin-resistant Staphylococcus Aureus Osteomyelitis Phase 3
Completed NCT02084147 - PET-MRI in Diagnosing Patients With Cancer, Cardiac Diseases, or Neurologic Diseases N/A
Terminated NCT02099240 - Patients Response to Early Switch To Oral:Osteomyelitis Study Early Phase 1
Withdrawn NCT02344511 - Dalbavancin vs Comparator in Pediatric Subjects With Acute Hematogenous Osteomyelitis Phase 3
Completed NCT00402064 - The Influence of Bisphosphonates in the Oral Cavity in Children N/A
Terminated NCT02168816 - Efficacy of Oral Antibiotic Therapy Compared to Intravenous Antibiotic Therapy for Osteomyelitis Phase 2
Completed NCT02685033 - Study on the Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Participants With Osteomyelitis Phase 2
Completed NCT02335905 - Ceftaroline for Treatment of Hematogenously Acquired Staphylococcus Aureus Osteomyelitis in Children Phase 1/Phase 2